A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women With Recurrent Clear Cell Carcinoma of the Ovary Fallopian Tube or Peritoneum
F
Frederick Stehman, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Not Recruiting
18 years - 100 years
Female
Phase
N/A
1 Location
Brief description of study
This phase II trial studies how well cabozantinib-s-malate works in treating patients with ovarian, fallopian tube, or primary peritoneal cavity cancer that has come back or is growing, spreading, or getting worse.
Detailed description of study
The purpose of this study is to evaluate the anti-tumor activity of cabozantinib (XL184) (cabozantinib-s-malate) in women with persistent or recurrent clear cell ovarian cancer, based on the proportion of patients who survive progression-free for at least 6 months and the proportion who have objective tumor response (complete or partial).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Recurrent Clear Cell Carcinoma of the Ovary Fallopian Tube or Peritoneum
-
Age: 18 years - 100 years
-
Gender: Female
Updated on
01 Aug 2024.
Study ID: 1506000856 (NRG-GY001)
